The current study in humanized E3L.CETP mice demonstrates that GIPR and GLP1R agonism additively attenuate hepatic steatosis, lower inflammation and ameliorate liver injury in the context of HFHC diet-induced NAFLD development. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.